Research ArticleOriginal Article
Open Access

Central nervous system manifestations of tuberous sclerosis complex

A single centre experience in Qatar

Munira Aden, Mahmoud O. Fawzi, Debra Prosser, Muhammad Ather, Mehak Raja, Moegamad A. Ederies, Khalid Al-Kharazi and Ata U. Maaz
Saudi Medical Journal November 2024, 45 (11) 1245-1252; DOI: https://doi.org/10.15537/smj.2024.45.11.20240444

References

  1. 1.↵
    1. O’Callaghan FJ,
    2. Shiell AW,
    3. Osborne JP,
    4. Martyn CN
    . Prevalence of tuberous sclerosis estimated by capture-recapture analysis. Lancet 1998; 351: 1490.
    OpenUrlPubMedWeb of Science
  2. 2.↵
    1. Jones AC,
    2. Shyamsundar MM,
    3. Thomas MW,
    4. Maynard J,
    5. Idziaszczyk S,
    6. Tomkins S, et al.
    Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet 1999; 64: 1305-1315.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Northrup H,
    2. Krueger DA
    . Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013; 49: 243-254.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Curatolo P,
    2. Moavero R,
    3. de Vries PJ
    . Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol 2015; 14: 733-745.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Caban C,
    2. Khan N,
    3. Hasbani DM,
    4. Crino PB
    . Genetics of tuberous sclerosis complex: implications for clinical practice. Appl Clin Genet 2016; 10: 1-8.
    OpenUrlPubMed
  6. 6.↵
    1. de Vries PJ,
    2. Whittemore VH,
    3. Leclezio L,
    4. Byars AW,
    5. Dunn D,
    6. Ess KC, et al.
    Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND checklist. Pediatr Neurol 2015; 52: 25-35.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Waltereit R,
    2. Feucht M,
    3. de Vries MC,
    4. Huemer J,
    5. Roessner V,
    6. de Vries PJ
    . [Neuropsychiatric manifestations in tuberous sclerosis complex (TSC): diagnostic guidelines, TAND concept and therapy with mTOR inhibitors]. Z Kinder Jugendpsychiatr Psychother 2019; 47: 139-153. [In German].
    OpenUrlPubMed
  8. 8.↵
    1. Beaumont TL,
    2. Limbrick DD,
    3. Smyth MD
    . Advances in the management of subependymal giant cell astrocytoma. Childs Nerv Syst 2012; 28: 963-968.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Ragel BT,
    2. Osborn AG,
    3. Whang K,
    4. Townsend JJ,
    5. Jensen RL,
    6. Couldwell WT
    . Subependymomas: an analysis of clinical and imaging features. Neurosurgery 2006; 58: 881-890.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Adriaensen ME,
    2. Schaefer-Prokop CM,
    3. Stijnen T,
    4. Duyndam DA,
    5. Zonnenberg BA,
    6. Prokop M
    . Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature. Eur J Neurol 2009; 16: 691-696.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Ruppe V,
    2. Dilsiz P,
    3. Reiss CS,
    4. Carlson C,
    5. Devinsky O,
    6. Zagzag D, et al.
    Developmental brain abnormalities in tuberous sclerosis complex: a comparative tissue analysis of cortical tubers and perituberal cortex. Epilepsia 2014; 55: 539-550.
    OpenUrlCrossRefPubMed
  12. 12.↵
    NPC. Monthly figures on total population. [Updated 2024; accessed 2024 Sep 23]. Available from: https://www.psa.gov.qa/en/statistics1/StatisticsSite/Pages/Population.aspx
  13. 13.↵
    GLMM. Qatar: population by nationality (Qatari/non-Qatari), gender and 5-year age group (2020). [Updated 2022; accessed 2024 Sep 23]. Available from: https://gulfmigration.grc.net/qatar-population-by-nationality-qatari-non-qatari-sex-and-five-year-age-group-2020/
  14. 14.↵
    WHO. Health data overview for the State of Qatar. [Updated 2023; accessed 2024 Sep 23]. Available from: https://data.who.int/countries/634
  15. 15.↵
    1. Humphrey A,
    2. Ploubidis GB,
    3. Yates JR,
    4. Steinberg T,
    5. Bolton PF
    . The early childhood epilepsy severity scale (E-Chess). Epilepsy Res 2008; 79: 139-145.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Almobarak S,
    2. Almuhaizea M,
    3. Abukhaled M,
    4. Alyamani S,
    5. Dabbagh O,
    6. Chedrawi A, et al.
    Tuberous sclerosis complex: clinical spectrum and epilepsy: a retrospective chart review study. Transl Neurosci 2018; 9: 154-160.
    OpenUrlPubMed
  17. 17.↵
    1. Ebrahimi-Fakhari D,
    2. Mann LL,
    3. Poryo M,
    4. Graf N,
    5. von Kries R,
    6. Heinrich B, et al.
    Incidence of tuberous sclerosis and age at first diagnosis: new data and emerging trends from a national, prospective surveillance study. Orphanet J Rare Dis 2018; 13: 117.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Dabora SL,
    2. Jozwiak S,
    3. Franz DN,
    4. Roberts PS,
    5. Nieto A,
    6. Chung J, et al.
    Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 2001; 68: 64-80.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Lim JS,
    2. Gopalappa R,
    3. Kim SH,
    4. Ramakrishna S,
    5. Lee M,
    6. Kim WI, et al.
    Somatic mutations in TSC1 and TSC2 cause focal cortical dysplasia. Am J Hum Genet 2017; 100: 454-472.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Onda H,
    2. Lueck A,
    3. Marks PW,
    4. Warren HB,
    5. Kwiatkowski DJ
    . Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J Clin Invest 1999; 104: 687-695.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. Kobayashi T,
    2. Minowa O,
    3. Kuno J,
    4. Mitani H,
    5. Hino O,
    6. Noda T
    . Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res 1999; 59: 1206-1211.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Comninos AN,
    2. Yang L,
    3. Abbara A,
    4. Dhillo WS,
    5. Bassett JHD,
    6. Todd JF
    . Frequent falls and confusion: recurrent hypoglycemia in a patient with tuberous sclerosis complex. Clin Case Rep 2018; 6: 904-909.
    OpenUrlPubMed
  23. 23.↵
    1. Bolton PF,
    2. Clifford M,
    3. Tye C,
    4. Maclean C,
    5. Humphrey A,
    6. le Maréchal K, et al.
    Intellectual abilities in tuberous sclerosis complex: risk factors and correlates from the tuberous sclerosis 2000 study. Psychol Med 2015; 45: 2321-2331.
    OpenUrlPubMed
  24. 24.↵
    1. Ebrahimi-Fakhari D,
    2. Franz DN
    . Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA). Expert Opin Pharmacother 2020; 21: 1329-1336.
    OpenUrlPubMed
  25. 25.
    1. Kingswood C,
    2. Bolton P,
    3. Crawford P,
    4. Harland C,
    5. Johnson SR,
    6. Sampson JR, et al.
    The clinical profile of tuberous sclerosis complex (TSC) in the United Kingdom: a retrospective cohort study in the clinical practice research datalink (CPRD). Eur J Paediatr Neurol 2016; 20: 296-308.
    OpenUrlPubMed
  26. 26.↵
    1. Nabbout R,
    2. Belousova E,
    3. Benedik MP,
    4. Carter T,
    5. Cottin V,
    6. Curatolo P, et al.
    Epilepsy in tuberous sclerosis complex: findings from the TOSCA study. Epilepsia Open 2018; 4: 73-84.
    OpenUrlPubMed
  27. 27.↵
    1. Toldo I,
    2. Brasson V,
    3. Miscioscia M,
    4. Pelizza MF,
    5. Manara R,
    6. Sartori S, et al.
    Tuberous sclerosis-associated neuropsychiatric disorders: a paediatric cohort study. Dev Med Child Neurol 2019; 61: 168-173.
    OpenUrlPubMed
  28. 28.↵
    1. de Vries PJ,
    2. Whittemore VH,
    3. Leclezio L,
    4. Byars AW,
    5. Dunn D,
    6. Ess KC, et al.
    Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND checklist. Pediatr Neurol 2015; 52: 25-35.
    OpenUrlCrossRefPubMed
  29. 29.
    1. D’Agati E,
    2. Moavero R,
    3. Cerminara C,
    4. Curatolo P
    . Attention-deficit hyperactivity disorder (ADHD) and tuberous sclerosis complex. J Child Neurol 2009; 24: 1282-1287.
    OpenUrlCrossRefPubMed
  30. 30.
    1. Vignoli A,
    2. La Briola F,
    3. Peron A,
    4. Turner K,
    5. Vannicola C,
    6. Saccani M, et al.
    Autism spectrum disorder in tuberous sclerosis complex: searching for risk markers. Orphanet J Rare Dis 2015; 10: 154.
    OpenUrlPubMed
  31. 31.↵
    1. O’Callaghan FJ,
    2. Martyn CN,
    3. Renowden S,
    4. Noakes M,
    5. Presdee D,
    6. Osborne JP
    . Subependymal nodules, giant cell astrocytomas and the tuberous sclerosis complex: a population-based study. Arch Dis Child 2008; 93: 751-754.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Adriaensen ME,
    2. Schaefer-Prokop CM,
    3. Stijnen T,
    4. Duyndam DA,
    5. Zonnenberg BA,
    6. Prokop M
    . Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature. Eur J Neurol 2009; 16: 691-696.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Bissler JJ,
    2. Kingswood JC,
    3. Radzikowska E,
    4. Zonnenberg BA,
    5. Belousova E,
    6. Frost MD, et al.
    Everolimus long-term use in patients with tuberous sclerosis complex: 4-year update of the EXIST-2 study. PLoS One 2017; 12: e0180939.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Krueger DA,
    2. Care MM,
    3. Holland K,
    4. Agricola K,
    5. Tudor C,
    6. Mangeshkar P, et al.
    Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010; 363: 1801-1811.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords